Effects of low-dose calcitriol combined with sevelamer carbonate on chronic kidney disease-mineral and bone abnormalities in hemodialysis patients

ObjectiveTo explore the effect of low-dose calcitriol combined with sevelamer carbonate on chronic kidney disease-mineral and bone abnormalities (CKD-MBD) in patients undergoing maintenance hemodialysis (MHD).

MethodsA total of 84 patients with MHD were selected as the research objects, and they were divided into the control group and observation group using a random number table method, with 42 cases in each group.Patients in the control group were given hemodialysis treatment and oral sevelamer carbonate, and the patients in the observation group were given oral administration of low-dose calcitriol on this basis for 2 months.The clinical efficacy, high-sensitivity C-reactive protein (hs-CRP), blood phosphorus, blood calcium and serum parathyroid hormone (iPTH) levels, abdominal aortic calcification (AAC) point before and 2 months after treatment, and the occurrence of adverse reactions were observed and compared.

ResultsAfter 2 months of continuous treatment, the total effective rate of the control group was 69.05%, which was higher than that of the observation group 88.10% (P < 0.05).The serum hs-CRP, phosphorus, and iPTH levels of the control group and the observation group were significantly lower than those before treatment, and the blood calcium level was significantly increased (P < 0.05 to P < 0.01).The serum hs-CRP, phosphorus, calcium and iPTH levels of the observation group were significantly lower than those of the control group (P < 0.01).After treatment, the AAC scores of the observation group and the control group were significantly increased, which of and the observation group was significantly lower than the control group (P < 0.01).The total incidence of adverse reactions in the observation group was 7.14%, the total incidence of adverse reactions in the control group was 11.90 %, and there was no significant difference between the two groups (P>0.05).

ConclusionsCombined application of low-dose calcitriol and sevelamer carbonate in MHD patients on the basis of conventional treatment can effectively reduce blood phosphorus and iPTH levels, improve the micro-inflammatory state, delay vascular calcification, and improve the therapeutic effect.It has good safety.